Women with pelvic
organ prolapse (POP) have bothersome
complaints
that significantly affect their quality of life. While native tissue
repair is associated with high recurrence rates, polypropylene knitted
implants have caused specific implant-related adverse events that
have detrimental, often irreversible, effects. We hypothesize that
surgical outcome can be improved with a tissue-engineered solution
using an absorbable implant that mimics the natural extracellular
matrix (ECM) structure, releases estrogen, and activates collagen
metabolism by fibroblasts as the main regulators of wound healing.
To this aim, we produced electrospun poly-4-hydroxybutyrate (P4HB)
scaffolds and biofunctionalized them with estradiol (E2). The cell–implant
interactions relevant for POP repair were assessed by seeding primary
POP vaginal fibroblasts isolated from patients on electrospun P4HB
scaffolds with 1%, 2%, or 5% E2 and without E2. To test our hypothesis
on whether ECM mimicking structures should improve regeneration, electrospun
P4HB was compared to knitted P4HB implants. We evaluated vaginal fibroblast
proliferation, ECM deposition, and metabolism by quantification of
collagen, elastin, and matrix metalloproteinases and by gene expression
analysis for 28 days. We established effective E2 drug loading with
a steady release over time. Significantly higher cell proliferation,
collagen-, and elastin deposition were observed on electrospun P4HB
scaffolds as compared to knitted P4HB. For this study, physical properties
of the scaffolds were more determinant on the cell response than the
release of E2. These results indicate that making these electrospun
P4HB scaffolds E2-releasing appears to be technically feasible. In
addition, electrospun P4HB scaffolds promote the cellular response
of vaginal fibroblasts and further studies are merited to assess if
their use results in improved surgical outcomes in case of POP repair.
Aim
Before the introduction of new biomaterials for prolapse surgery, animal studies on the host response are required. Unfortunately, large variation in study design hampers obtaining an overview of the safety and efficacy, and translation to clinical practice. Our aim is to systematically review the literature on all outcome measures describing the host response in animal studies assessing the biocompatibility of urogynecologic surgical mesh implants for prolapse surgery. Furthermore, by meta‐analysis, we aim to assess the effect of implantation and compare this to control animals receiving sham surgery or native tissue repair.
Methods
We performed a systematic search from inception to August 2020. Since this is an explorative study we included original, controlled, and noncontrolled animal studies describing any host response to the implant. Quantitative outcome measures reported ≥10 times in ≥2 articles were eligible for meta‐analysis.
Results
Fifty articles were included in the qualitative synthesis and 36 articles were eligible for meta‐analysis. In total, 154 outcome measures were defined and classified into (1) histomorphology, (2) biomechanics and, (3) macroscopic morphology. Animals with vaginal implants demonstrated significantly increased M1 and M2 macrophages, MMP‐2, neovascularization, TNF‐α, and stiffness, and lower vaginal contractility compared to control animals.
Conclusion
The host response significantly differs in animals after vaginal mesh implantation compared to control animals, both pro‐ and anti‐inflammatory. However, we observed a paucity in the uniformity of reported outcomes. For future animal studies, we propose the development of a core outcome set, which ideally predicts the host response in women.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.